*
*Uveitis|128473001
*
* specifically
refers|439980006
to inflammation|257552002
of the middle layer|255562008|399488007
of the eye,|81745001|244486005
termed
the "uvea"|74862005
but
in common usage|72906007|277889008
may
refer|439980006
to any inflammatory process|415178003
involving|248448006
the interior
of the eye.|81745001|244486005

Uveitis|128473001
is
estimated to|414135002
be
responsible|394851003
for approximately 10%|26175008
of the blindness
in the United States.|223688001

Uveitis|128473001
requires
an urgent referral|134403003
and
thorough examination|5880005
by an ophthalmologist|422234006
along
with urgent treatment to|103391001|276239002|103391001|416118004
control|31509003
the inflammation.|257552002

Uveitis|128473001
may
be
classified|73504009
anatomically
into _anterior_,|255549009
_intermediate_,|11896004
_posterior_|255551008
and
_panuveitic_ forms,|246176004
based|418836005
on which part|260726005
of the eye|81745001|244486005
is
primarily
affected|247591002|248448006
by the inflammation.|257552002

In 2004,
a group|261586004|160481000|389109008
of international uveitis specialists|128473001|309395003
convened
in Baltimore,
MD,
to
standardize
the method|260686004|272394005
of reporting data|223458004
in uveitis clinical trials,|128473001|110465008
including|55919000
anatomical classification.|36298004|73504009

The results|394617004
of this meeting|229057006
were
published
in the American Journal
of Ophthalmology|394594003
in 2005.[2]

Medical signs|74188005|72670004
of Anterior Uveitis|410692006|4927003
include|55919000
dilated ciliary vessels,|255381004|85803001|59820001|255381004|244201001|59820001
presence|386397008
of cells|4421005
and
flare
in the anterior chamber,|31636006
and
keratic precipitates ( " KP ")|246998009
on the posterior surface|255551008|410678000
of the cornea.|28726007|181162001

In severe inflammation,|103624008
as
in the photograph,|257444003
there
may
be
evidence|18669006
of a hypopyon.|87807004

Old episodes|272131007
of uveitis|128473001
can
be
identified|7882003
by pigment|65863008
deposits|46595003
on lens,|78076003|181169005
KP's,|223582006
and
festooned pupil|392406005|35146001
on dilation|25322007|71025006|363105001
of pupil.|392406005|35146001

Most common|4757001|72906007
:

Intermediate uveitis normally only|314429009
affects|4065008
one eye.|421379005|81745001|421379005|244486005

Less common|276139006|72906007|263796003|72906007
is
the presence|386397008
of pain|22253000
and
photophobia.[3]|409668002

Inflammation|257552002
in the back of the eye|255551008|81745001|255551008|244486005
is
commonly
characterised
by
:

The cause|134198009
of non-infectious uveitis|128473001
is
unknown|261665006
but
there
are
some strong genetic factors|260404005|3950001|260404005|255395001
that
predispose
disease onset|217315002
including|55919000
HLA-B27[4][5]|34453005
and
the PTPN22 genotype.[6]

Recent evidence|6493001|18669006
has
pointed
to reactivation
of Herpes simplex,|88594005
varicella zoster|38907003|4740000|19551004|4740000
and
other viruses|74964007|49872002
as important causes|134198009
of developing
what
was
previously
described
as idiopathic anterior uveitis.|231947004

Bacterial infection|301811001
is
another significant contributing factor|386134007
in developing uveitis.[8]|128473001

Uveitis|128473001
may
be
a
(normal|17621005|258744000
)
immune response to|35024006
fight|248005005
an infection
inside the eye_[citation|81745001|244486005
needed|410525008|103325001
_].

While
representing
the minority|410599005|255606000
of patients|116154003
with uveitis,|128473001
such possible infections|371930009|60022001
include|55919000
:

Onset|77374008
of Uveitis|128473001
can
broadly
be
described
as a failure|76797004
of the Ocular immune system|81745001|116003000|281004000|116003000|116003000
and
disease|64572001
results|394617004
from inflammation|257552002
and
tissue destruction.|85756007|64597002

Uveitis|128473001
is
driven|129060000|247750002
by the Th17 T cell sub-population|57184004|261089000|385436007|57184004|261089000|389109008|57184004|118555000|385436007|57184004|118555000|389109008
that bear T-cell receptors|106970005|81926004
specific|69658003
for proteins|88878007
found|404684003
in the eye.|81745001|244486005

These
are
often|70232002
not
deleted
centrally
whether
due to ocular antigen|81745001|7120007|281004000|7120007|7120007
not
being
presented|246105001
in the thymus|9875009
and
are
therefore
not negatively
selected
or
a state|398070004
of anergy
is
induced to|16404004
prevent
self targeting.

Autoreactive T cells,|57184004
therefore,
must
normally
be
held|421139008
in check|52101004|360160009|18720000|360160009
by the suppressive environment wrought|244840000|276339004
by Microglia|63483002
and
dendritic cells
in the eye.|81745001|244486005

These cells|4421005
produce
large amounts|255509001|107651007
of TGF beta|52095000|260989008
and
other suppressive cytokines,|74964007|244840000|75777003
including|55919000
IL-10,|11267006
to
prevent
damage|37782003
to the eye|81745001|244486005
by reducing inflammation|260400001|257552002
and
causing T cells to|23981006|57184004
differentiate|263933003
to inducible T reg cells.|16404004|4421005

Innate immune stimulation|255386009|122545008
by bacteria|409822003
and
cellular stress|4421005|262188008
is
normally
suppressed|245780008
by myeloid suppression|255391005|80633008|255391005|258761002
while
inducible Treg cells|16404004|4421005
prevent
activation
and
clonal expansion|47308002
of the autoreactive Th1
and
Th17 cells|4421005
that
possess
potential to|30207005
cause|23981006|134198009
damage|37782003
to the eye.|81745001|244486005

Whether
through infection
or
other causes,|74964007|134198009
this balance|249982003|78933003|282295000
can
be
upset|224977004
and
autoreactive T cells|57184004
allowed
to
proliferate
and
migrate
to the eye.|81745001|244486005

Upon entry
to the eye,|81745001|244486005
these cells|4421005
may
be
returned|7528007
to an inducible Treg state|16404004|398070004
by the presence|386397008
of IL-10|11267006
and
TGF-beta|52095000|260989008
from microglia.|63483002

Failure|76797004
of this mechanism|257544000
will
lead|88488004
to neutrophil|116712007
and
other leukocyte recruitment|74964007|52501007|2724004
from the peripheral blood|119273009
through IL-17 secretion.|224058004|46242002|223609006|46242002

Tissue destruction|85756007|64597002
is
mediated|73510009
by non-specific macrophage activation|10003008|58986001
and
the resulting cytokine cascades[13] Serum TNF-?|42752001|75777003|67922002
is
significantly
elevated|75540009
in cases|398241000|413769002
while
IL-6|30965005
and
IL-8|44459007
are
present|52101004|246105001
in significantly higher quantities|75540009|107651007|371879000|107651007
in the Aqueous humour|425460003|280587006
in patients|116154003
with
both
quiescent
and
active uveitis.|55561003|128473001

These
are
inflammatory markers
that non-specifically
activate
local macrophages|255470001|58986001
causing|23981006
tissue damage.|37782003

Myriad conditions|260905004
can
be
associated|47429007
with uveitis,|128473001
including|55919000
diseases|64572001
with major extra-ocular involvement,|255603008|81745001|248448006|255603008|281004000|248448006|255603008|248448006
as well as
syndromes
confined
to the eye.|81745001|244486005

In anterior uveitis,|410692006|4927003
no associated condition|47429007|260905004
or
syndrome
is
found|404684003
in approximately one-half|26175008|421379005
of cases.|398241000|413769002

However,
anterior uveitis|410692006|4927003
is
often|70232002
one|421379005
of the syndromes
associated|47429007
with HLA-B27.|34453005

Presence|386397008
this type|261664005
of HLA allele|47038001|9109004
has
a relative risk|125677006|30207005|29920004|30207005
of evolving|59381007
this disease|64572001
by approximately 15%.[15]|26175008

Systemic disorders|370117001
that
can
be
associated|47429007
with uveitis|128473001
include|55919000
:
[16]

In many cases,|398241000|413769002
uveitis|128473001
is
not
associated|47429007
with a systemic|31099001
(i.e.|42146005|22971001

extraocular
)
condition|260905004
:
the inflammation|257552002
is
confined
to the eye.|81745001|244486005

In some
of these cases,|398241000|413769002
the presentation|246105001
in the eye|81745001|244486005
is
characteristic
of a described syndrome,
and
include|55919000
the following diagnoses|255260001|439401001
:

Masquerade syndromes|410577002
are
ophthalmic disorders|371405004
that clinically
present|52101004|246105001
as
either
an anterior|255549009
or
posterior uveitis,|43363007
but
are
not primarily inflammatory.

The following|255260001
are
some
of the most common|4757001|72906007
:

Diagnosis|439401001
is
performed|398166005
using|260676000
a dilated fundus examination|255381004|65784005|5880005|255381004|414003|5880005|255381004|87009000|5880005|255381004|27485007|5880005|255381004|5880005
for Posterior Uveitis|43363007
which
presents|52101004|246105001
with white spots|413773004|271807003|413773004|285305004|185984009|271807003|185984009|285305004|371251000|271807003|371251000|285305004
across the retina|5665001|181171005
along
with retinitis|399463004
and
vasculitis.|31996006

Uveitis|128473001
is
typically
treated|28995006
with glucocorticoid steroids,|419933005|116566001
either
as topical eye drops|385125006|359540000|385125006
(prednisolone acetate|96334000
)
or
oral therapy|260548002|276239002
with corticosteroids.|79440004

Prior to the administration|413454004|416118004
of corticosteroids,|79440004
corneal ulcers|91514001
must
be
ruled|10828004
out.|255529000

This
is
typically
done
using|260676000
a fluoresence dye test.|258021009

In addition|260364009
to corticosteroids,|79440004
topical cycloplegics,|412172009|359540000|412172009
such as atropine|372832002
or
homatropine,|372864009
may
be
used.|394850002

Successful treatment|182985004
of active uveitis|55561003|128473001
will
see|281004000
an increase|260366006
in T-regulatory cells|115399009
in the eye|81745001|244486005
which
is
likely to|2931005
contribute
to disease regression.|64572001|48386003

In some cases|398241000|413769002
an injection|28289002|385218009|129326001
of PSTTA
(posterior subtenon triamcinolone acetate|255551008|116594009|429850007
)
may
also
be
given|419582001
to
reduce|260400001
the swelling|423666004|442672001
of the eye.|81745001|244486005

[21]

Antimetabolite medications,|372785000|410942007
such as methotrexate|387381009
are
often|70232002
used|394850002
for recalcitrant
or
more aggressive cases|242762006|61372001|398241000|242762006|61372001|413769002|242762006|398241000|242762006|413769002
of uveitis.|128473001

Experimental treatments|276239002
with Infliximab|386891004
or
other anti-TNFs' infusions|74964007|447826007
may
prove|277025001
helpful.

On May 7,
2012
the journal investigative Ophthalmology & Visual Science|433497004|394594003|255374006
stated|398070004
that "Metformin|372567009
inhibits|61511001
the process|415178003
that
causes|134198009
that inflammation".|257552002

The scientists|308027003
believe
that
it
has
a good chance|20572008
of
being
rapidly|418694008
adopted|160496001
as an anti-uveitis drug,|128473001|410942007
since
Metformin|372567009
is
already
used|394850002
so widely|223528007
as a therapy|276239002
for diabetes.[22]|73211009

The prognosis|20481000
is
generally good|20572008
for those
who
receive
prompt diagnosis|439401001
and
treatment,|276239002|416118004
but
serious complication|42745003|116223007|42745003|263718001
(
including|55919000
cataracts,|247053007|95722004
glaucoma,|23986001
band keratopathy,|35055000
retinal edema|6141006
and
permanent vision loss|6934004
)
may
result|394617004
if left|7771000
untreated.|25265005

The type|261664005
of uveitis,|128473001
as well as
its severity,|272141005
duration,|103335007
and
responsiveness|80074009
to treatment|276239002|416118004
or
any associated illnesses,|47429007|39104002
all factor
in
to the outlook.[[1]]|225464009
(http
:
//www.intelihealth.com/IH/ihtIH/EMIHC000/9339/10942.html
)

Uveitis|128473001
affects|4065008
roughly 1
in 4500 people|125676002
and
is
most common|4757001|72906007
between the ages 20|424144002
to 60
most
affected|247591002|248448006
,
with men|339947000
and
women|224526002
affected|247591002|248448006
equally.

In the west,
Anterior Uveitis|410692006|4927003
accounts
for
between 50%
and
90%|264705001|264703008
of Uveitis cases|128473001|398241000|128473001|413769002
while
in Asian countries|223571003
the proportion|8212001
drops|426684005|404218003
to
be
between 28%
and
50%.[23]|264657009

M
:
EYE|81745001|244486005

anat(g/a/p/phys/devp/prot|258795003|304383000

noco/cong/tumr,
epon

proc,
drug|410942007
(S1A/1E/1F/1L

Arthritis ? Dermatomyositis ? _soft tissue_|3723001|396230008|181607009|3723001|396229003|181607009
(Myositis,|26889001
Synovitis/Tenosynovitis,|416209007|67801009
Bursitis,|84017003
Enthesitis,|359643005
Fasciitis,|36948007
Capsulitis,|6858004
Epicondylitis,|73583000
Tendinitis,|34840004
Panniculitis|22125009

_female|248152002|224526002
:
_ Oophoritis ? Salpingitis ? Endometritis ? Parametritis ? Cervicitis ? Vaginitis ? Vulvitis ? Mastitis|76047005|88157006|78623009|280483007|37610005|30800001|63144007|45198002|76047005|88157006|78623009|280483007|37610005|237091009|63144007|45198002

_male|248153007
:
_ Orchitis ? Epididymitis ? Prostatitis ? Balanitis ? Balanoposthitis|197983000|9713002|44882003|46090001

